Prognostic value of IMP3 immunohistochemical expression in triple negative breast cancer

Sjekloča, Nikoleta; Tomić, Snježana; Mrklić, Ivana; Vukmirović, Filip; Vučković, Ljiljana; Lovasić, Ingrid Belas; Maras–Šimunić, Marina

doi:10.1097/md.0000000000019091

Cited by 12 publications

(11 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Growing evidence has demonstrated that m6A modification is closely associated with tumorigenesis, tumor differentiation, tumor proliferation, tumor invasion and worse survival in BC patients, including METTL3, METTL14, WTAP, ALKBH5, IGF2BP2, IGF2BP3, and FTO [3][4][5][6][7][8][9][10][11][12][13][14]. In addition, the m6A regulator IGF2BP3 was associated with reduced cell apoptosis, larger tumor sizes, higher grade, higher clinical stage, necrosis, and CK5/6 expression and further worsened the DFS and OS of BC patients [4,15,16]. However, the m6A regulator EIF3A had no association with age, tumor size, or differentiation grade.…”

Section: Introductionmentioning

confidence: 99%

Expression and clinical prognostic value of m6A RNA methylation modification in breast cancer

Zheng

Qian

et al. 2021

Biomark Res

View full text Add to dashboard Cite

Background N6-methyladenosine(m6A) methylation modification affects the tumorigenesis, progression, and metastasis of breast cancer (BC). However, the expression characteristics and prognostic value of m6A modification in BC are still unclear. We aimed to evaluate the relationship between m6A modification and clinicopathological characteristics, and to explore the underlying mechanisms. Methods Three public cohorts and our clinical cohort were included: 1091 BC samples and 113 normal samples from the TCGA database, 1985 BC samples from the METABRIC database, 1764 BC samples from the KM Plotter website, and 134 BC samples of our clinical cohort. We collected date from these cohorts and analyzed the genetic expression, gene-gene interactions, gene mutations, copy number variations (CNVs), and clinicopathological and prognostic features of 28 m6A RNA regulators in BC. Results This study demonstrated that some m6A regulators were significantly differenially expressed in BCs and their adjacent tissues, and also different in various molecular types. All 28 studied m6A regulators exhibited interactions. KIAA1429 had the highest mutation frequency. CNVs of m6A regulators were observed in BC patients. The expression of the m6A regulators was differentially associated with survival of BC. Higher CBLL1 expression was associated with a better prognosis in BC than lower CBLL1 expression. Functional analysis showed that CBLL1 was related to the ESR1-related pathway, apoptosis-related pathway, cell cycle pathway and immune-related pathway in BC. Conclusions m6A RNA modification modulated gene expression and thereby affected clinicopathological features and survival outcomes in BC. CBLL1 may be a promising prognostic biomarker for BC patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Expression and clinical prognostic value of m6A RNA methylation modification in breast cancer

Zheng

Qian

et al. 2021

Biomark Res

View full text Add to dashboard Cite

show abstract

“…IMP3, as already mentioned, is a cytoplasmic marker found in many malignancies [1,2]. Since it shows a tendency towards higher expression in more aggressive neoplasms, it has been considered as a promising prognostic indicator [1][2][3][4][5][6]. However, while the number of studies suggesting the biological and clinical relevance of IMP3 is increasing, there is also a rising number of papers revealing apparent discrepancies with respect to the frequency of expression in some types of cancer [2].…”

Section: Discussionmentioning

confidence: 99%

“…It is required for the migration of cells forming the roof plate of the neural tube which suggests that IMP3 may play an important role in promoting cell migration [1,2]. Moreover, IMP3 has gained considerable interest as a cancer-associated protein as it has been reported in a variety of human malignancies and has been linked to advanced disease stage and adverse clinical outcomes [1][2][3][4][5][6]. These data indicate that it may represent a valuable prognostic marker in human cancer.…”

Section: Introductionmentioning

confidence: 99%

Immunohistochemical Expression of IMP3 in Cutaneous Basal Cell Carcinoma

Bartoš

2022

Galician med. j.

View full text Add to dashboard Cite

Background. Insulin-like growth factor-II mRNA-binding protein 3 (IMP3) is an oncofetal protein upregulated in tumor cells during carcinogenesis. It has been linked to adverse clinical outcome in many malignancies. This study was aimed to evaluate an immunohistochemical expression status of IMP3 in cutaneous basal cell carcinoma (BCC) and to correlate it with the Ki-67 index values. Methods. Biopsy specimens from 32 cases of BCC were enrolled into this analysis. All samples were immunohistochemically stained for IMP3 (Clone 69.1) and Ki-67 antigen (Clone MIB-1). Results. IMP3 showed a weak expression in 11 (34.4%) cases, a moderate expression in 11 (34.4%) cases, a strong expression in 5 (15.6%) cases, and negative staining in 5 (15.6%) cases. Among seven BCCs exhibiting aggressive-growth features, all but one showed weak reactivity. In contrast, all five BCCs manifesting strong IMP3 positivity consisted of the indolent-growth histologic subtypes. BCCs with infiltrative histomorphology did not appear to have a tendency towards more striking production of IMP3. There was no significant relationship between the IMP3 expression status and the proliferation status (Ki-67 ≤ 50% vs. Ki-67 > 50%) of the tumor tissue (p > 0.05). Conclusions. The vast majority of cutaneous BCCs express IMP3, suggesting this oncoprotein is implicated in BCC carcinogenesis. However, more pronounced expression does not seem to be associated with aggressive-growth phenotype of BCC or higher proliferative activity of neoplastic cells.

show abstract

“…Majority of the studies in literature have reported IMP3 positivity in breast carcinoma ranging from 33 to 35.6% [ 16 – 18 ]. Contrary to this, in the present study, IMP3 immunopositivity was seen in 86.7% of the breast carcinoma cases.…”

Section: Discussionmentioning

confidence: 99%

“…IMP3 staining intensity also showed significant association with tumor histological grade ( p = 0.009) and TNM stage ( p = 0.036). Sjekloča et al also reported a significant association between IMP3 positivity and tumor size and TNM stage [ 18 ]. Similar to our study results, Walter et al also found a significantly higher expression of IMP3 in higher grade breast tumors ( p < 0.001) [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of IMP3 and Its Role as an Epithelial-Mesenchymal Transition Promoter in Breast Carcinoma

Jha

Diwaker

Arora

et al. 2023

Indian J Surg Oncol

View full text Add to dashboard Cite

Breast carcinoma is now the most common cancer in the world. In view of its high mortality, there is a need to identify new prognostic biomarkers. Both IMP3 and SLUG have been implicated in cancer metastasis. This was a retrospective study conducted on 60 breast carcinoma cases using tissue microarrays. Demographic and clinicopathological details were recorded. Immunohistochemistry for IMP3 and SLUG was performed and evaluated in terms of percentage-cell-positivity and intensity of staining. A proforma was used to store data and was analyzed using SPSS v20. IMP3 positivity was found in 87% breast carcinoma cases and was significantly associated with tumor size ( p = 0.03) and TNM stage ( p = 0.024). IMP3 staining intensity showed significant association with histological grade ( p = 0.009), TNM stage ( p = 0.036), and molecular subtype ( p = 0.03). SLUG immunoexpression was seen in 90% breast carcinoma cases and was significantly associated with TNM stage ( p = 0.006). SLUG staining intensity was significantly associated with age ( p = 0.025) and TNM stage ( p = 0.004). IMP3 and SLUG immunopositivity and their staining intensities were significantly associated ( p <0.001, p <0.001). IMP3 and SLUG percentage cell positivities were also significantly correlated ( p <0.001). IMP3 and SLUG are, thus, poor prognostic markers with a role in tumor invasiveness and aggressiveness via epithelial-mesenchymal transition. Hence, IMP3 and SLUG-based targeted therapies may be useful in the treatment of breast carcinoma.

show abstract

Prognostic value of IMP3 immunohistochemical expression in triple negative breast cancer

Cited by 12 publications

References 33 publications

Expression and clinical prognostic value of m6A RNA methylation modification in breast cancer

Expression and clinical prognostic value of m6A RNA methylation modification in breast cancer

Immunohistochemical Expression of IMP3 in Cutaneous Basal Cell Carcinoma

Prognostic Value of IMP3 and Its Role as an Epithelial-Mesenchymal Transition Promoter in Breast Carcinoma

Contact Info

Product

Resources

About